Answers are grounded in this paper and cite their sources.
This trial demonstrated that early response assessment supported therapeutic titration (omitting radiotherapy in RERs with CR; augmenting chemotherapy in SERs with PET-positive disease). Strategies directed toward improved response assessment and risk stratification may enhance tailoring of treatment to patient characteristics and response.
No takes yet. Share an insight, caveat, or question.
Friedman et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: